Hologic case takes toll on Lunar
Bone densitometry firm Lunar said its ongoing legal battle withHologic will result in unexpectedly high legal costs that willeat into profits for the fourth quarter (end-June). Lunar willprobably post profits for the quarter that are lower comparedto the
Bone densitometry firm Lunar said its ongoing legal battle withHologic will result in unexpectedly high legal costs that willeat into profits for the fourth quarter (end-June). Lunar willprobably post profits for the quarter that are lower comparedto the same period a year ago, when Lunar had net income of $1.7million. The Madison, WI, company did not project a specific figurefor fourth-quarter earnings.
Lunar said legal costs associated with its patent battle withHologic have been higher than expected (SCAN 6/7/95). The caseis scheduled to go to trial Aug. 14 and is expected to last twoweeks, according to the company.
On the positive side, Lunar said it expects to show sharplyhigher revenues when it makes its full quarterly earnings announcementAug. 4. Revenues are expected to be $12.7 million, up 37% comparedto the $9.3 million in sales reported in the same period in 1994.Medicare reimbursement for dual-energy x-ray absorptiometry hasbeen driving sales growth for DEXA scanners this year (SCAN 12/28/94).
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Study Explores Impact of Insurance on Treatment and Referrals for Patients with Uterine Fibroids
February 19th 2025Women with uterine fibroids and Medicaid coverage are significantly more likely to be treated with uterine artery embolization than those with commercial insurance, according to newly published research.
